agilon health (AGL) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
2 Jun, 2026Opening remarks and agenda
Emphasis on long-term value creation, strategic engagement, and operational execution as priorities for the board and management in 2025 and into 2026.
Introduction of board members, management team, independent auditor, legal counsel, and inspector of election.
Board and executive committee updates
Board remains aligned with management, providing guidance and oversight to ensure strategic priorities and sustainable results.
CEO Tim O'Rourke introduced, highlighting his experience and role in advancing mission and strategy.
Shareholder proposals
Three proposals presented: election of three Class II directors, ratification of independent auditors, and advisory approval of executive compensation.
Board recommended voting in favor of all proposals.
Latest events from agilon health
- Q2 2026 delivered strong revenue growth and profitability, prompting raised full-year guidance.AGL
Q2 2026 - Cost trends are improving as growth, clinical initiatives, and payer negotiations drive future performance.AGL
2024 Wells Fargo Healthcare Conference - Profitability surged in Q1 2026, prompting raised full-year guidance for key metrics.AGL
Q1 2026 - Tim O'Rourke named CEO and Director with new compensation terms; no changes to voting matters.AGL
Proxy filing - Virtual annual meeting to vote on directors, auditor, and executive pay, with board support.AGL
Proxy filing - Proxy covers director elections, auditor ratification, pay-for-performance, and ESG priorities.AGL
Proxy filing - Shareholders approved a reverse stock split and adjournment proposal, both backed by the Board.AGL
EGM 2026 - 2026 guidance targets breakeven EBITDA and $5.5B revenue after cost discipline and transformation.AGL
Q4 2025 - Q3 revenue up 28% to $1.45B, but net loss widened to $118M and guidance was lowered.AGL
Q3 2024